Burfiralimab
Product Specifications
UNSPSC Description
Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies[1].
Target Antigen
Interleukin Related; SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection;Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/burfiralimab.html
Purity
95.20
Solubility
10 mM in DMSO
Smiles
[Burfiralimab]
References & Citations
[1]Prasenohadi Prasenohadi, et al. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11(11):2961.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99490/Burfiralimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99490/Burfiralimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2460809-80-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
